Clinical Trials Using Gonadotropin-releasing Hormone Analog

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gonadotropin-releasing Hormone Analog. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 43
1 2 Next >

  • Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer

    This phase III trial studies whether the addition of definitive treatment (radiation or surgical removal) of the primary tumor to standard systemic therapy for patients with prostate cancer, may help prevent the cancer from the spreading to other parts of their body. Removing the prostate by either surgery or radiation therapy in addition to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
    Location: 252 locations

  • Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery

    This randomized phase II / III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or without docetaxel after surgery may kill any remaining tumor cells.
    Location: 238 locations

  • CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

    This phase III trial compares the addition of rucaparib to enzalutamide with enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to androgen-deprivation therapy. Testosterone is a hormone made mainly in the testes and is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It also plays role in prostate cancer development. Enzalutamide may help fight prostate cancer by blocking the use of testosterone by the tumor cells for growth. PARPs are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as rucaparib, can keep PARPs from working , so tumor cells can't repair themselves. This may stop tumor cells from growing. Giving enzalutamide and rucaparib may prolong patients’ survival and / or prevent their cancer from growing or spreading for a longer time. It may also help doctors learn if a mutation in any of the specific DNA repair (homologous recombination) genes is helpful in selecting the most appropriate treatment for the patient.
    Location: 32 locations

  • Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial

    This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Abiraterone acetate may help fight prostate cancer by lowering the amount of testosterone made by the body. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding abiraterone acetate and apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
    Location: 31 locations

  • A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

    This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
    Location: 26 locations

  • Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) after Surgery for Men with High-Risk Prostate Cancer, The ERADICATE Study

    This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood. Testosterone is a hormone made mainly in the testes and is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It also plays a role in prostate cancer development. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. Giving darolutamide with ADT may work better in eliminating or reducing the size of the cancer and / or prevent it from returning compared to ADT alone in patients with prostate cancer.
    Location: 13 locations

  • Darolutamide and Radiation Therapy for the Treatment of Prostate Cancer, the INTREPiD Trial

    This phase II trial studies how well darolutamide and different types of radiation therapy work in treating patients with prostate cancer. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using darolutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells. External beam radiation therapy (EBRT) is a type of radiation therapy in which high-energy beams are delivered to the tumor from outside of the body. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving darolutamide and different types of radiation therapy may work better compared to standard hormonal therapy in treating patients with prostate cancer.
    Location: 10 locations

  • Nivolumab, Docetaxel, and Androgen Deprivation Therapy for the Treatment of Metastatic, Hormone-Sensitive Prostate Cancer with DNA Damage Repair Defects or Inflamed Tumors

    This phase II trial studies how well nivolumab, docetaxel, androgen deprivation therapy (ADT) work in treating patients with hormone-sensitive prostate cancer with deoxyribonucleic acid (DNA) damage repair defects or inflamed tumors that has spread to other places in the body (metastatic). Testosterone can cause the growth of prostate cancer cells. ADT, or hormonal therapy, may help fight prostate cancer by cutting off the supply of testosterone. Nivolumab is an antibody (a type of human protein) that works by stimulating the body’s immune system to recognize and fight cancer cells. Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormonal therapy and chemotherapy may make cancer cells more recognizable to the immune system, and make cancer cells more susceptible to nivolumab immunotherapy. The purpose of this study is to examine the activity and safety of hormonal therapy combined with docetaxel chemotherapy and nivolumab immunotherapy for patients with prostate cancer.
    Location: 8 locations

  • A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

    Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.
    Location: 10 locations

  • Study of Abiraterone, Atezolizumab, Lupron, and Radiation Therapy for the Treatment of Men with Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer, SAABR Study

    This phase II trial studies how well abiraterone acetate, atezolizumab, lupron, and stereotactic body radiotherapy works for the treatment of men with hormone-sensitive prostate cancer that has spread to different parts of the body (metastatic). Abiraterone acetate works by decreasing the production of the male sex hormone (testosterone) that causes prostate cancer to grow. The steroid drug prednisone is given with abiraterone acetate to reduce or prevent some of its side effects. Lupron (leuprolide) is a hormone treatment that reduces levels of testosterone, which slows the growth of prostate cancer. Atezolizumab is a type of drug called a PD-L1 blocker; it blocks a protein located on the surface of some tumor cells and immune cells that can act as a “brake” on the immune system. Blocking this protein releases the brakes, allowing the immune system to function more efficiently to identify and attack cancer cells. Stereotactic body radiotherapy delivers very precisely targeted high-dose radiation in less time than standard radiation therapy, which reduces potential damage to healthy tissues near the targeted treatment area. Adding atezolizumab and stereotactic body radiotherapy to treatment with abiraterone acetate, prednisone, and lupron may boost the immune system's ability to identify and destroy cancer cells, which may prevent the cancer from getting worse.
    Location: 8 locations

  • Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

    Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments
    Location: 7 locations

  • Docetaxel and Trastuzumab before Surgery for the Treatment of HER2-Positive Stage II-III Breast Cancer in Nigerian Women, the ARETTA Trial

    This phase II trial studies the effect of docetaxel and trastuzumab before surgery in treating HER2 positive stage II-III breast cancer in Nigerian women. Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. This study is being done to determine how effective and safe docetaxel and trastuzumab are before surgery in Nigerian women with breast cancer.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

    This phase II trial studies palbociclib isethionate together with anastrozole and to see how well they work in treating patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) stage II or III breast cancer. Palbociclib isethionate may stop tumor growth by blocking an enzyme needed for cell division and growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving palbociclib isethionate together with anastrozole may be an effective treatment for ER+ HER2- breast cancer.
    Location: 4 locations

  • A Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

    This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of GDC-9545 combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.
    Location: 6 locations

  • Goserelin Acetate and Pembrolizumab in Treating Patients with Advanced Androgen-Receptor Positive Salivary Gland Cancer

    This phase II trial studies how well goserelin acetate and pembrolizumab work in treating patients with androgen-receptor positive salivary gland cancer that has spread to other places in the body (metastatic). Many salivary gland tumors need hormones (called androgens) to grow. Goserelin acetate blocks the androgen receptors on tumor cells and may cause them to stop growing or die. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving goserelin acetate and pembrolizumab together may work better in treating patients with androgen-receptor positive salivary gland cancer compared to giving either drug on its own.
    Location: 5 locations

  • Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

    Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective: - To compare the overall survival in both treatment arms - To evaluate the objective response rate in both treatment arms - To evaluate the duration of response in both treatment arms - To evaluate the clinical benefit rate in both treatment arms - To evaluate progression-free survival on next line of therapy - To evaluate the pharmacokinetics of amcenestrant, and palbociclib - To evaluate health-related quality of life in both treatment arms - To evaluate the time to first chemotherapy in both treatment arms - To evaluate safety in both treatment arms
    Location: 8 locations

  • Evaluation of Response to Abiraterone Acetate, Prednisone, and Androgen Deprivation Therapy by Race or Ethnicity in Patients with Metastatic Prostate Cancer

    This phase II trial is to find out whether men from different races and ethnic groups with prostate cancer that has spread to other places in the body (metastatic) respond differently to the combination of androgen deprivation therapy (either a shot or surgery to remove the testicles) plus the drug abiraterone acetate and prednisone. Abiraterone acetate lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Anti-inflammatory drugs, such as prednisone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Information gained form this study may help the researchers better understand whether certain factors, such as race or ethnicity play a role in how a patient responds to cancer treatment. This may help identify better and more personalized treatments in the future.
    Location: 3 locations

  • Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

    QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib (Kisqali® Prescribing Information, Investigator Brochure). The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on / 1 week off schedule. The purpose of the study is to explore whether a reduced dosing regimen of 400 mg ribociclib orally QD 3 weeks on / 1 week off may decrease the risk of QTc prolongation without compromising the efficacy of ribociclib in combination with an NSAI in pre- and postmenopausal women with HR-positive, HER2-negative aBC who have received no prior therapy for advanced disease. The risks of other AEs of special interest, such as neutropenia and hepatobiliary toxicity will be evaluated in this study as well. Approximately 350 patients will be randomly assigned to one of the below treatment arms in a 1:1 ratio: Experimental arm (Arm 1) - Ribociclib 400 mg QD 3 weeks on / 1 week off + NSAI (+ goserelin in premenopausal women): 175 patients Control arm (Arm 2) - Ribociclib 600 mg QD 3 weeks on / 1 week off + NSAI (+ goserelin in premenopausal women): 175 patients Randomization will be stratified by the presence of lung and / or liver metastases (yes versus no).
    Location: 3 locations

  • Conventional Androgen Deprivation Therapy with or without Abiraterone, Prednisone, and Apalutamide for the Treatment of High Risk Prostate Cancer after Radiation and Male Hormone Deprivation Therapy

    This phase III trial studies conventional male hormone (androgen) deprivation therapy (also called hormonal therapy), abiraterone acetate (abiraterone), prednisone, and apalutamide to see how well this combination works compared with conventional androgen deprivation therapy alone in treating patients with prostate cancer who have already received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose prostate specific antigen (PSA) remains detectable despite having received at least 6 months of hormonal therapy. Androgen deprivation therapy blocks the function of male hormones, including testosterone which prostate cancer cells use to grow and spread. Adding abiraterone, prednisone, and apalutamide to the conventional androgen deprivation therapy may work better than conventional androgen deprivation therapy alone in treating patients with detectable PSA who have received radiation therapy and are being treated with long-term hormonal therapy for their prostate cancer.
    Location: 5 locations

  • Androgen Deprivation Therapy, Pembrolizumab, and Stereotactic Body Radiation Therapy with or without TLR9 Agonist SD-101 in Treating Patients with Metastatic Prostate Cancer

    This randomized phase II trial studies how well androgen deprivation therapy, pembrolizumab, and stereotactic body radiation therapy with or without TLR9 agonist SD-101 in treating patients with prostate cancer that has spread to other places in the body. Androgen can cause the growth of tumor cells. Androgen deprivation therapy, such as leuprolide acetate, prednisone, and abiraterone acetate may lessen the amount of androgen made by the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. SD-101 may stimulate the body’s immune response by increasing the ability of immune cells to recognize and kill tumor cells. It is not yet known whether giving androgen deprivation therapy, pembrolizumab, and stereotactic body radiation therapy with or without TLR9 agonist SD-101 may work better in treating patients with prostate cancer.
    Location: 2 locations

  • Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies

    This phase II trial studies how well testosterone therapy followed by enzalutamide or abiraterone acetate works in treating patients with prostate cancer that has become worse or spread on combined androgen therapies. Androgens, such as testosterone, can cause the growth of prostate cancer cells. Androgen therapies, such as enzalutamide and abiraterone acetate, suppress or block the production or action of testosterone. Rapid treatment with testosterone may make the cancer cells become sensitive to retreatment with enzalutamide or abiraterone acetate. Giving testosterone prior to enzalutamide or abiraterone acetate may have an effect on the growth of prostate cancer in men who have not responded to long term therapy to lower testosterone in their blood (castrating therapy).
    Location: 2 locations

  • Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study

    This phase II trial studies the effect of hormonal therapy given after (adjuvant) pertuzumab and trastuzumab in treating patients with hormone receptor positive, HER2 positive breast cancer. The drugs trastuzumab and pertuzumab are both monoclonal antibodies, which are disease-fighting proteins made by cloned immune cells. Estrogen can cause the growth of breast cancer cells. Hormonal therapy, such as letrozole, anastrozole, exemestane, and tamoxifen, block the use of estrogen by the tumor cells. Giving hormonal therapy after pertuzumab and trastuzumab may kill any remaining tumor cells in patients with breast cancer.
    Location: Dana-Farber Cancer Institute, Boston, Massachusetts

  • Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Using PET / CT Imaging

    This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen [PSA] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography / computed tomography (PET / CT) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as positron emission tomography / computed tomography (PET / CT), may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET / CT results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
    Location: 2 locations

  • Abemaciclib and Androgen Deprivation Therapy for the Treatment of Localized High-Risk or Locally Advanced Prostate Cancer

    This phase II trial studies the effect of abemaciclib and androgen deprivation therapy in treating patients with prostate cancer that has not spread to other parts of the body (localized) and is high-risk, or has spread to nearby tissue or lymph nodes (locally advanced). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Since prostate cancer is driven prominently by high testosterone levels, drugs used in androgen deprivation therapy, such as goserelin acetate and leuprolide acetate, act to reduce the levels of testosterone and thus slow the growth of prostate cancer. Abemaciclib may work with androgen deprivation therapy to control growth and spread of prostate cancer so as to make the patient’s tumor better receptive to radiation therapy and improve outcomes to radiation therapy.
    Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

  • Androgen Deprivation Therapy (Leuprolide and Degarelix) and Chemoimmunotherapy (Cemiplimab and Docetaxel) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

    This phase II trial studies the side effects of androgen deprivation therapy (leuprolide and degarelix) and chemoimmunotherapy (cemiplimab and docetaxel) and to see how well they work in treating patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic). Androgen can cause the growth of prostate cancer cells. Hormone therapy using leuprolide and degarelix may fight prostate cancer by blocking the use of androgen by the tumor cells. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this study is to determine if the addition of immunotherapy to chemotherapy and androgen deprivation therapy, is safe and improves response to therapy.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York


1 2 Next >